{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:40:49Z","timestamp":1793922049818,"version":"4.8.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82001870"],"award-info":[{"award-number":["82001870"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Neoadjuvant immunotherapy has shown promising short-term outcomes of perioperative treatments for resectable non-small cell lung cancer (NSCLC) and is expected to release long-term survival benefits. Here, we reported the long-term prognostic value of <jats:sup>18<\/jats:sup>F-FDG PET\/CT over \u223ca 5-year follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>A total of 35 patients with NSCLC (29 males and 6 females; median age, 62 y) received 2 doses of sintilimab, followed by complete tumor resection and PET\/CT scans at baseline and post-neoadjuvant stages. We investigated the prognostic value of PET\/CT for overall survival (OS) and progression-free survival (PFS), focusing on metabolic parameters of primary tumors, mediastinal lymph nodes, lymphoid organs, and immune-related adverse events on imaging.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>During a median follow-up of 62.6 months, patients with low primary tumor metabolism (SUL<jats:sub>max<\/jats:sub> \u22646.6, SUL<jats:sub>peak<\/jats:sub> \u22644.0\/3.9, or SUL<jats:sub>mean<\/jats:sub> \u22642.7) at post-neoadjuvant scan were alive and disease-free, demonstrating improved OS (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.07, 0.07, and 0.09) and significantly enhanced PFS (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.01, 0.02, and 0.02); those with low metabolic tumor volume \u226449.3 or total lesion glycolysis \u226441.0 at post-neoadjuvant scan also had significantly improved OS (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03 and 0.05). Patients with low lymph node metabolism (SUL<jats:sub>max<\/jats:sub> \u22644.6) at baseline scan had significantly improved PFS (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This is the first study to report the long-term prognostic value of <jats:sup>18<\/jats:sup>F-FDG PET\/CT for resectable NSCLC after neoadjuvant immunotherapy. Low primary tumor metabolism at post-neoadjuvant scan and low lymph node metabolism at baseline scan are promising prognostic markers for improved clinical outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005910","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:00:17Z","timestamp":1749013217000},"page":"577-587","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic Value of 18F-FDG PET\/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC"],"prefix":"10.1097","volume":"50","author":[{"given":"Xiuli","family":"Tao","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine (PET-CT Center)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine (PET-CT Center)"},{"name":"Department of Diagnostic Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine (PET-CT Center)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine (PET-CT Center)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugeng","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine (PET-CT Center)"},{"name":"Department of Diagnostic Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"R1-20250619","first-page":"242","article-title":"Recurrence after surgery in patients with NSCLC","volume":"3","author":"Uramoto","year":"2014","journal-title":"Transl Lung Cancer Res"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"100244","DOI":"10.1016\/j.esmoop.2021.100244","article-title":"Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review","volume":"6","author":"Ulas","year":"2021","journal-title":"ESMO Open"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2020.01.017","article-title":"Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC","volume":"15","author":"Gao","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat Med"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12967-022-03472-x","article-title":"Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021","volume":"20","author":"Burton","year":"2022","journal-title":"J Transl Med"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/1078-0432.CCR-22-2994","article-title":"Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer","volume":"29","author":"Rosner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jtho.2022.04.012","article-title":"Three-year follow-up of neoadjuvant programmed cell death protein-1 inhibitor (sintilimab) in NSCLC","volume":"17","author":"Zhang","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","article-title":"FDG PET\/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature","volume":"46","author":"Aide","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1111\/1759-7714.13664","article-title":"Predictive value of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography for PD-L1 expression in non-small cell lung cancer: a systematic review and meta-analysis","volume":"11","author":"Seol","year":"2020","journal-title":"Thorac Cancer"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"20864","DOI":"10.1002\/cam4.6665","article-title":"Predictive value of (18) F-FDG PET\/CT and serum tumor markers for tumor mutational burden in patients with non-small cell lung cancer","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1007\/s00259-024-06794-8","article-title":"[(18)F]FDG-PET\/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal","volume":"51","author":"Masse","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"e007628","DOI":"10.1136\/jitc-2023-007628","article-title":"Total metabolic tumor volume on (18)F-FDG PET\/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy","volume":"12","author":"Tricarico","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-020-04711-3","article-title":"The efficiency of (18)F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer","volume":"47","author":"Tao","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"suppl 1","key":"R15-20250619","doi-asserted-by":"crossref","first-page":"122s","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.clon.2010.11.001","article-title":"Adaptive 18fluoro-2-deoxyglucose positron emission tomography\/computed tomography-based target volume delineation in radiotherapy planning of head and neck cancer","volume":"23","author":"Moule","year":"2011","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2967\/jnumed.107.044362","article-title":"18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?","volume":"48","author":"Hellwig","year":"2007","journal-title":"J Nucl Med"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1007\/s00259-022-05904-8","article-title":"Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [(18)F]FDG PET\/CT imaging: quantitative analysis of [(18)F]FDG uptake in primary tumors and metastatic lymph nodes","volume":"49","author":"Wang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1245\/s10434-021-10564-3","article-title":"PET-uptake reduction into lymph nodes after neoadjuvant therapy is highly predictive of prognosis for patients who have thoracic esophageal squamous cell carcinoma treated with chemoradiotherapy plus esophagectomy","volume":"29","author":"Nagaki","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/cncr.22518","article-title":"Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET\/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients","volume":"109","author":"Kim","year":"2007","journal-title":"Cancer"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s00259-009-1155-4","article-title":"18F-FDG PET\/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country: consideration of lymph node calcification and distribution pattern to improve specificity","volume":"36","author":"Lee","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s00259-020-05103-3","article-title":"Assessing immune organs on (18)F-FDG PET\/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients","volume":"48","author":"Prigent","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1007\/s00259-022-05788-8","article-title":"Prognostic value of immunotherapy-induced organ inflammation assessed on (18)FDG PET in patients with metastatic non-small cell lung cancer","volume":"49","author":"Humbert","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3348\/kjr.2013.14.1.1","article-title":"Prognostic significance of volume-based PET parameters in cancer patients","volume":"14","author":"Moon","year":"2013","journal-title":"Korean J Radiol"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00029330-200701020-00010","article-title":"18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer","volume":"120","author":"Zhang","year":"2007","journal-title":"Chin Med J (Engl)"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00259-017-3806-1","article-title":"Metabolic activity by (18)F-FDG-PET\/CT is predictive of early response after nivolumab in previously treated NSCLC","volume":"45","author":"Kaira","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1007\/s00330-016-4292-8","article-title":"The diagnostic ability of (18)F-FDG PET\/CT for mediastinal lymph node staging using (18)F-FDG uptake and volumetric CT histogram analysis in non-small cell lung cancer","volume":"26","author":"Lee","year":"2016","journal-title":"Eur Radiol"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10147-020-01783-x","article-title":"Prognostic impact of preoperative FDG-PET positive lymph nodes in lung cancer","volume":"26","author":"Endoh","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41698-020-00135-2","article-title":"Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes","volume":"4","author":"Ling","year":"2020","journal-title":"NPJ Precis Oncol"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1038\/s41467-021-25188-0","article-title":"Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer","volume":"12","author":"Cascone","year":"2021","journal-title":"Nat Commun"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","article-title":"Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics","volume":"46","author":"Seban","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"12137","DOI":"10.1038\/s41598-021-91608-2","article-title":"Prognostic significance of bone marrow and spleen (18)F-FDG uptake in patients with colorectal cancer","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"key":"R36-20250619","first-page":"9","article-title":"Cancer and inflammation","author":"Munn","year":"2017","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1","volume":"96","author":"Mekki","year":"2018","journal-title":"Eur J Cancer"},{"key":"R38-20250619","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1007\/s00259-020-04815-w","article-title":"FDG PET\/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment","volume":"47","author":"Iravani","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R39-20250619","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"R40-20250619","doi-asserted-by":"crossref","first-page":"e241285","DOI":"10.1001\/jamanetworkopen.2024.1285","article-title":"Neoadjuvant-adjuvant vs neoadjuvant-only PD-1 and PD-L1 inhibitors for patients with resectable NSCLC: an indirect meta-analysis","volume":"7","author":"Zhou","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T14:00:23Z","timestamp":1750341623000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005910"}},"subtitle":["A Five-year Follow-up Study"],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005910","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"2024-11-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}